{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:26:38Z","timestamp":1783596398265,"version":"3.55.0"},"reference-count":40,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,6,23]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      For rheumatoid arthritis (RA), the\n                      <jats:italic>HLA-DRB1<\/jats:italic>\n                      \u2018shared epitope\u2019 (SE) allele has been proposed as a predictive biomarker for the effectiveness of mainly abatacept and other biologic disease-modifying antirheumatic drugs (bDMARDs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore the relative impact of SE positivity on the effectiveness of different bDMARDs in European patients with RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nested cohort study in the Swiss (Swiss Clinical Quality Management) and Danish (DANBIO) rheumatology registries. Patients with RA who initiated bDMARD treatment and had available DNA samples to define SE were included. Four bDMARD groups were defined: abatacept, tumour necrosis factor inhibitors (TNFi), rituximab, tocilizumab. Patients were matched 1:1 using propensity scores and the effectiveness compared between patients being SE positive versus SE negative. For sensitivity, the number of SE alleles was included. Primary end point was treatment retention (crude by SE status, adjusted Cox regression analyses including relevant covariates). Secondary end points were low disease activity (LDA) and remission (1, 2 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 5248 treatment courses initially identified, 464 patients in each of the four bDMARD groups were matched (SE negative: 31%, one SE allele: 48%, two alleles: 21%). For all bDMARD groups, crude 1-year treatment retention was unaffected by SE status. Cox regression analyses showed non-significant HRs for SE-positive versus SE-negative patients: abatacept 0.99 (95% CI 0.71 to 1.38), TNFi 1.01 (0.66 to 1.54), rituximab 1.14 (0.71 to 1.84), tocilizumab 1.48 (0.92 to 2.40). LDA and remission rates were unaffected by SE status for all four bDMARDs. Sensitivity analyses showed similar results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the current study, the SE was not associated with bDMARD effectiveness in patients with RA of mainly European ancestry.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2026-006788","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:10:19Z","timestamp":1783595419000},"page":"e006788","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of the shared epitope on the effectiveness of biologic antirheumatic agents in European patients with rheumatoid arthritis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1210-4347","authenticated-orcid":false,"given":"Axel","family":"Finckh","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland"},{"name":"Geneva Center for Inflammation Research (GCIR), University of Geneva, Geneva, Switzerland"},{"name":"SCQM Biobank Study Group, SCQM Registry, Foundation SCQM, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine S","family":"Courvoisier","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2854-3632","authenticated-orcid":false,"given":"Romain","family":"Aymon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Mongin","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saedis","family":"Saevarsdottir","sequence":"additional","affiliation":[{"name":"Amgen deCODE genetics, Reykjavik, Iceland"},{"name":"Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjav\u00edk, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingileif","family":"Jonsdottir","sequence":"additional","affiliation":[{"name":"Amgen deCODE genetics, Reykjavik, Iceland"},{"name":"Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjav\u00edk, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Stefansson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjav\u00edk, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-6818","authenticated-orcid":false,"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[{"name":"DANBIO Registry, Danish Rheumatologic Biobank and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Rigshospitalet Glostrup, Glostrup, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8769-6167","authenticated-orcid":false,"given":"Burkhard","family":"Moeller","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Immunology and Allergology, Inselspital Universitatsspital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Villard","sequence":"additional","affiliation":[{"name":"Geneva Center for Inflammation Research (GCIR), University of Geneva, Geneva, Switzerland"},{"name":"Plateforme des laboratoires de th\u00e9rapie cellulaire et de transplantation, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-9009","authenticated-orcid":false,"given":"Kim","family":"Lauper","sequence":"additional","affiliation":[{"name":"Geneva Center for Inflammation Research (GCIR), University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Danish Rheumatologic Biobank Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the SCQM Biobank Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8931-8482","authenticated-orcid":false,"given":"Bente","family":"Glintborg","sequence":"additional","affiliation":[{"name":"DANBIO Registry, Danish Rheumatologic Biobank and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Rigshospitalet Glostrup, Glostrup, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"2026070904101008000_12.3.e006788.1","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","article-title":"The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries","volume":"60","author":"Courvoisier","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026070904101008000_12.3.e006788.2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40744-021-00401-0","article-title":"Baseline anti-citrullinated protein antibody status and response to abatacept or non-TNFi biologic\/targeted synthetic DMARDs: US observational study of patients with RA","volume":"9","author":"Harrold","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2026070904101008000_12.3.e006788.3","first-page":"455","article-title":"Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis","volume":"38","author":"Alemao","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2026070904101008000_12.3.e006788.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102400"},{"key":"2026070904101008000_12.3.e006788.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3435"},{"key":"2026070904101008000_12.3.e006788.6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2103726"},{"key":"2026070904101008000_12.3.e006788.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780301102"},{"key":"2026070904101008000_12.3.e006788.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207942"},{"key":"2026070904101008000_12.3.e006788.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-56987-2","article-title":"Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis","volume":"14","author":"Cha","year":"2024","journal-title":"Sci Rep"},{"key":"2026070904101008000_12.3.e006788.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211430"},{"key":"2026070904101008000_12.3.e006788.11","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15030","article-title":"The double shared epitope: Its impact on clinical features and ultrasound findings in rheumatoid arthritis","volume":"27","author":"Michitsuji","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"2026070904101008000_12.3.e006788.12","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02612-w","article-title":"Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis","volume":"23","author":"Hirose","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2026070904101008000_12.3.e006788.13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s42358-024-00352-4","article-title":"Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive","volume":"64","author":"Harrold","year":"2024","journal-title":"Adv Rheumatol"},{"key":"2026070904101008000_12.3.e006788.14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4078\/jrd.2022.29.3.171","article-title":"Clinical implications of shared epitope and anti-citrullinated peptide antibody in patients with rheumatoid arthritis","volume":"29","author":"Jung","year":"2022","journal-title":"J Rheum Dis"},{"key":"2026070904101008000_12.3.e006788.15","unstructured":"Weinblatt M , Emery P , Bykerk V , et al . Subcutaneous abatacept vs adalimumab head-to-head comparison in adults with early, dual seropositive rheumatoid arthritis, positive for the shared epitope HLA class II risk alleles, and an inadequate response to methotrexate: results from a phase 3 trial [abstract]. Arthritis Rheumatol 2024;76."},{"key":"2026070904101008000_12.3.e006788.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226024"},{"key":"2026070904101008000_12.3.e006788.17","unstructured":"Introduction to Bio- and Genome Bank Denmark (RBGB). Available: https:\/\/www.rbgb.dk\/en\/om-rbgb\/ [Accessed 11 May 2026]."},{"key":"2026070904101008000_12.3.e006788.18","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S99490"},{"key":"2026070904101008000_12.3.e006788.19","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S141438"},{"key":"2026070904101008000_12.3.e006788.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019325","article-title":"Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study","volume":"8","author":"Kringelbach","year":"2018","journal-title":"BMJ Open"},{"key":"2026070904101008000_12.3.e006788.21","doi-asserted-by":"publisher","DOI":"10.2147\/clep.S392416"},{"key":"2026070904101008000_12.3.e006788.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221307"},{"key":"2026070904101008000_12.3.e006788.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221754"},{"key":"2026070904101008000_12.3.e006788.24","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3964"},{"key":"2026070904101008000_12.3.e006788.25","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2018-213412","article-title":"Systematic approach demonstrates enrichment of multiple interactions between non-HLA risk variants and HLA-DRB1 risk alleles in rheumatoid arthritis","volume":"77","author":"Diaz-Gallo","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026070904101008000_12.3.e006788.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222586"},{"key":"2026070904101008000_12.3.e006788.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.27740"},{"key":"2026070904101008000_12.3.e006788.28","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000040","article-title":"The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries","volume":"1","author":"Finckh","year":"2015","journal-title":"RMD Open"},{"key":"2026070904101008000_12.3.e006788.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12982-017-0060-8","article-title":"On hazard ratio estimators by proportional hazards models in matched-pair cohort studies","volume":"14","author":"Shinozaki","year":"2017","journal-title":"Emerg Themes Epidemiol"},{"key":"2026070904101008000_12.3.e006788.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221477"},{"key":"2026070904101008000_12.3.e006788.31","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.124"},{"key":"2026070904101008000_12.3.e006788.32","doi-asserted-by":"crossref","DOI":"10.1186\/ar2111","article-title":"The rheumatoid arthritis shared epitope increases cellular susceptibility to oxidative stress by antagonizing an adenosine-mediated anti-oxidative pathway","volume":"9","author":"Ling","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"2026070904101008000_12.3.e006788.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.03.035"},{"key":"2026070904101008000_12.3.e006788.34","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02607-7","article-title":"HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA","volume":"23","author":"Rigby","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2026070904101008000_12.3.e006788.35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42324-6","article-title":"Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis","volume":"13","author":"Inoue","year":"2023","journal-title":"Sci Rep"},{"key":"2026070904101008000_12.3.e006788.36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.43298","article-title":"Comparative effectiveness of abatacept versus adalimumab in shared epitope positive and negative patients with rheumatoid arthritis","volume":"78","author":"Yap","year":"2026","journal-title":"Arthritis & Rheumatology"},{"key":"2026070904101008000_12.3.e006788.37","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10067-017-3547-3","article-title":"The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis","volume":"36","author":"Alpizar-Rodriguez","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2026070904101008000_12.3.e006788.38","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11767","article-title":"Revisiting the link between HLA-DRB1 alleles and autoantibodies in rheumatoid arthritis: association of non-shared epitope alleles *09 and *15 with high levels of anti-citrullinated peptide\/protein antibodies","volume":"7","author":"Lagutkin","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"2026070904101008000_12.3.e006788.39","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1542\/hpeds.2023-007259","article-title":"How to interact with interactions: what clinicians should know about statistical interactions","volume":"13","author":"Cotter","year":"2023","journal-title":"Hosp Pediatr"},{"key":"2026070904101008000_12.3.e006788.40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.37737\/ace.22005","article-title":"Introduction to matching in case-control and cohort studies","volume":"4","author":"Iwagami","year":"2022","journal-title":"Ann Clin Epidemiol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-006788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:10:22Z","timestamp":1783595422000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-006788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,9]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2026-006788"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-006788","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}